🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
51.80
-5.58 (-9.72%)
At close: Nov 20, 2026, 4:00 PM EST
51.07
-0.73 (-1.41%)
After-hours: Nov 20, 2026, 7:57 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

Atera demand exceeded expectations and supply, with interest reaching beyond existing Xenium users and planned production scaling from Q1. Single-cell pricing transition is expected to continue for another couple of quarters, while spatial AI and clinical applications advance.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

Great. We are going to kick it off. I am Tycho Peterson from the Life Science team. Pleased to have 10x with us. Welcome, Serge. Welcome, Adam. Maybe just kick it off with a quick recap from 3Q, just thinking a little bit about some of the momentum here as we head into next year. Obviously, new product cycle. We have a number of things going on. Just, what were the positives and negatives out of the quarter and in 2027?

Serge Saxonov
CEO, 10x

Yeah, no, probably the biggest positive and continuing story of this year has been the momentum on the Atera. We came into this year really enthused about the potential of the platform. It was really fun to tell the world about it back in April. Consistently since that point, it has been really fun to be out there and just see the customer enthusiasm, which has been translating into all manner of kinds of metrics in terms of order flow, in terms of funnel, just the resonance with customers out there. I think that continued to be. That was the big story of Q2. That continued to be, I would say, the big story of Q3.

Now, overlay on top of that, we always knew that once we announced the Atera, there is going to be some pressure on our business when it comes to existing spatial business and consumables. Coming into Q3, we expected that to be the biggest pinch point. What has been a really nice, also positive development is the continuing strength in the consumable in the existing business that we saw. A lot of the quarter played out roughly as we expected, as we communicated, but there definitely were some upsides that we saw in our numbers, specifically on the spatial consumables, but also just continuing enthusiasm for Atera.

Of course, we also saw really nice trends continuing along on our single-cell business, keep driving reaction volume, and just overall the big macro trends while there is the academic and government funding are still pressured. Overall, the macro environment has been trending, I would say, in our favor, supported by this continued interest in AI and also with our current slate of products and translational work.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

How is the early user base evolved for Atera relative to your initial assumptions around high-throughput clinical spatial labs? Just talk a little bit about the evolution of the customer base.

Serge Saxonov
CEO, 10x

Yeah. Just to be clear, it's very early, right? We literally told the world for the first time in April that this thing existed. No one expected it. No one could imagine that that set of capabilities was coming, was going to be available to the world. Our initial go-to-market strategy naturally was focused on customers that are already existing Xenium instrument owners, users. The idea being that those are the people that would be most ready to ramp, to take advantage of Atera, and to really spread the word and serve the rest of the ecosystem out of the gate.

Now, certainly those customers have been our focus, and there's a lot of interest from existing Xenium instrument owners, but also a very large fraction of the initial orders, and even more so for the funnel, is from people who are not currently owners of Xeniums. Some of them are actually new to spatial completely. So that's been really great to see. The breadth of interest, the breadth of applications, and the depth has been really, I would say, even in excess of our expectations. Our expectations were pretty high going into the launch.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

I guess, obviously still early days, but just thinking about the breadth of customers and pull-through assumptions, maybe one for Adam, how do we think about the framework for pull-through, and when will we get more granularity there?

Adam Taich
CFO, 10x

Yeah. Well, I hate to sound like a broken record, but it's really early. We've just got such a small N out there. Most of the customers so far from an order perspective are really interested in the whole transcriptome. We're really trying to prioritize instruments because we've got demand outstrips supply. We're trying to make sure they're getting instruments into the hands of folks that have got projects lined up, that are well-funded, ready to start pulling through consumables. We'll give more color on that when we get into Q1 and guidance.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

You gave some numbers on the scalability for next year, which was helpful. I guess, are there rate-limiting factors we need to think about to scale beyond that that are important?

Adam Taich
CFO, 10x

Yeah. I mean, what we've said, just to reiterate, was that we would sell 50 Ateras this year. One, just want to be clear, that doesn't mean we're at that point where we're building 50. It's an ambitious target, but it's a target we feel really confident in. As we get into Q1, feel confident we'll be able to build 50 a quarter. Maybe just as important, if not more important, is we're really optimizing for customer success. Ensuring that we've got field service engineer capacity and capability to get these things installed. As you can imagine, nothing out of the ordinary, but I mean, each one of the very small N thus far has had some little tweak, whether that's a site readiness issue, something else that may have happened in shipping.

Really trying to work out and iron out any of those kinks. Then having field application support on site just to make sure that the customer's up and running, successful, that they've got a consumables order that's ready to go, so that when we leave, through telemetry, we can actually see they're running, they're successfully running the instrument.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

I guess in terms of expanding the user base beyond the Xenium customers, just talk about some of the leading indicators. I mean, obviously there's grant filings, but what else are you tracking as you think about expanding the market?

Serge Saxonov
CEO, 10x

Yeah. So, first of all, the most direct measure is just like, okay, the customers are actually putting in the money and the people in the funnel. Like I said earlier, there's a greater than expected fraction of them that are new to Xenium instruments. So that's a really encouraging sign to begin with. Then you kind of look at all the different sort of applications, right, that are being used and coming online. So certainly AI is a big deal. We can talk a lot more about it, but in many ways, Atera is perfectly built for this new era of AI, and not by accident, right? That is kind of a core premise of the company, is to build tools that can measure biology, the right kind of biology at massive scale and high resolution.

Atera kind of perfectly fits this moment in a way that no previous spatial technology really did. We're seeing a lot of interest, kind of a very large scale, like different institutions, whether it's kind of big consortia or companies, biotech companies, AI kind of native companies that are gearing up to use this technology. Or, kind of made a reference on our earnings call to companies that are like diagnostics companies that are sitting on large numbers of clinical samples that are really valuable samples, that they now can apply this technology to extract maximum information content from and correlate it to clinical data as well. So, I've been actually finding just in my personal conversation with customers, I was just, one of the things you take advantage of when you come out to these conferences, you go and you see customers.

I saw a few yesterday, and there's examples, many, where customers have had cohorts of samples, really precious samples that they've gotten. Like an example of this customer yesterday, a breast cancer researcher who collected a large cohort, pre-treatment, on treatment, post-treatment, and has been waiting for the right technology to come along to now analyze and has looked at many things along the way. Now Atera kind of fits the need exactly. We see many, many of these kinds of examples. You get translational research, kind of figuring out the huge thing now with all the new therapies coming online in oncology, figuring out mechanisms of resistance and predicting response to therapy. So all of that. Remember too, Xenium in itself kind of was actually a really rapidly growing platform, the best platform in spatial biology and was rapidly growing.

In fact, in the absence of Atera, we would be talking about this as the most amazing thing ever. It's probably the most prominent, the fastest growing platform out there. Atera is coming into a market that's already growing really robustly, but kind of blowing the doors off the whole thing, and I think taking it to the whole next level.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

By the way, Xenium's still growing. Consumables are up like mid-single digit, right? Were you surprised at kind of the resilience of Xenium?

Adam Taich
CFO, 10x

Yeah, I think that maybe as Serge noted, I think that was one of the pleasant surprises in Q3. We'd anticipated and built into guidance for the year, because obviously we knew Atera was coming before you all did. So when we gave the, which was tricky giving annual guidance back in whatever, February, knowing we were going to launch this thing in April. But we sort of worked our way to incorporate all that. We actually thought that the slowdown between Q2 and Q3 would be more prominent, and we had like mid-single digit, if I recall. Q on Q growth still grew with Atera, or rather Xeniums, still had very strong growth in Q3. We would expect that to slow down. I mean, that's our anticipation.

It's kind of what we factored into the Q4 guide, that we wouldn't necessarily see continued sequential growth as more Ateras get placed. I don't think that that's going to immediately fall off a cliff, but that's one of the things we're going to be keeping a close eye on, is what does sort of pull-through look like at those customers that now have had Xenium but also now have Atera installed.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

I guess, going back to AI foundation models, I guess Atera versus Chromium Perturb-seq, how do you think about both those contributing to models? Which do you think could be more meaningful, I guess, in the next couple years?

Serge Saxonov
CEO, 10x

Yeah, that's a really good question, and certainly something we're watching carefully as the world is kind of evolving really rapidly on that front. Perturb-seq is a very powerful, very exciting application. It's kind of interesting because sort of the original papers came out back in 2016, and we've been waiting for a while for the application to kind of really start taking off. The last few years really has been, as a function of us introducing technologies that are just a lot more scalable for single-cell analysis, prices coming down on the sequencing side, and AI, of course. Now you can run these massive experiments and make sense of the data, then feed it into foundation models and to kind of virtual models of biology.

We expect that this is like relative to what is going to happen in the future, we're still very much in the kind of embryonic state, where in both first principles, the scale at which we need to run these experiments is much larger than what has been done so far, and also what we're hearing from customers, right? The biggest experiments right now are sort of in orders of millions, maybe getting to tens of millions. But if you listen to the people that are really forefront, talking about hundreds of billions of kind of cells.

Once Chromium has been kind of the workhorse and enabler of all of this, going back to the very beginning, and especially now, and especially with Flex Apex, is something that we have been actually really pressing and kind of working with our customers to enable them. We're seeing that in particular picking up in the biopharma, a lot of adoption of Apex there. They're kind of investing in automation to build out and scale. As we look to the future, and I would say especially kind of watching what's been happening over the last several months since we announced Atera, we do think more and more of this kind of large-scale foundation model building will be based off of spatial data, and more and more will be kind of getting built with Atera as the foundation.

And in fact, even perturbation screens, so where, if you think about individual cells, dissociated cells, and doing these kinds of large-scale screens on them, as you are pushing up the scale to higher and higher levels, I think Atera will become the natural kind of technology for that as well, just because of the scale that it delivers. Still kind of relatively early days, and it is evolving rapidly, but this is one of the big updates that I have been kind of having in my head as I have been talking to customers, is more and more interest in Atera, and Atera really being the kind of the workhorse of a lot of these applications in the future. And of course, for us, kind of just economics business-wise, it is great, right? We like the business consolidating onto Atera for many reasons.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

And you are still seeing a double-digit reaction growth, I think, in Flex and Apex, right? I mean, when does that Because consumables are up 1% on single-cell, but you have got kind of the pricing. Just walk through the mechanics of when you kind of get through the pricing headwinds there and

Serge Saxonov
CEO, 10x

Yeah. So this is something, this strategy we have been communicating for quite some amount of time, right? Especially over the course of the past year. We launched Flex Apex a year ago. There was a lot of pent-up demand right out of the gate last Q4. And Apex is meant to be considerably lower price per reaction, but much more scalable. And so the whole equation has been kind of drive more volume, that naturally drives down average reaction price, especially as people are stepping down from more expensive kits, but it is driving a lot of volume. And actually, the amount of volume we have been seeing is, I would say, in excess of what we had expected as we embarked on that strategy. And it has been quarter- after- quarter- after- quarter. And it is a very dynamic kind of process, right?

We have been sort of managing, pressing on that volume, but kind of managing the price at the same time, and the result is dynamic. The more you press on the Apex conversion, the more it pulls down the average reaction price, the more it pulls down the top line, while people are gearing up to increase, to kind of do more and then make up for that lower price point. And so we are still in that sort of dynamic kind of period, where we are going through that transition. I would say another couple of quarters, we expect for that to be the case. Then, sort of I expect a measure of sort of equilibrium to be reached where sort of the incremental growth on Apex will contribute to the top line. But yeah, we are still kind of in that dynamic stage of the-

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

When consumables combine, can get back to double-digit growth? Any timeframe?

Serge Saxonov
CEO, 10x

Well, overall, the way that we're thinking now, especially with Atera coming on so strong, is looking at the sum total of our consumables here, and that's what we're optimizing for the business, and feeling really strong, really, really good about where things are trending now, and especially as we head into next year. There's a lot of momentum for the business. You can sort of get lost a lot of the time in all the puts and takes around which product is getting converted into which other product. But if you step back and just look at the amount of demand out there and momentum, and the dollars that people are gearing up to spend here, things are looking really, really strong.

Obviously, we'll talk more about, as we enter next year, and in terms of giving guide and all that.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

Maybe just touch on what you're doing with Catalyst Research Services, right? You've got, I think, over 100 customers signed up. Just talk a little bit about the strategy there and

Serge Saxonov
CEO, 10x

Yeah. This has been another kind of interesting development too. For us, historically, we've always been very much a product-focused company. It's all about putting products out there. We had a small service, a little bit for Xenium, to do demos for customers ahead of instrument purchases. We invested in that as well for Atera, with Catalyst Research Services, expanded a bit. But the amount of demand has been quite dramatic for that service. And it is definitely in the service of people testing things out before investing in their instruments, getting some data to put into grants, to advocate within their institutions to buy an instrument themselves. But the scope, the scale, and diversity of those projects has been a really nice positive, I would say, surprise to us.

We actually had to allocate a few more instruments to the service to satisfy that demand, and it keeps going strong. I do think there's a secular trend towards somewhat more services, where people ultimately are interested in the data and the insights, and less so necessarily of getting their own sort of equipment sometimes. And so that's something that we're also watching and will be enabling as necessary as we go forward.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

And the customer profile there is mostly academic? I mean, just talk a little bit about, and what has it taught you around repeat usage, conversion into instrument purchases? What are some of the learnings?

Serge Saxonov
CEO, 10x

Yeah. I mean, look, so far, way too early. I mean, we've got a big backlog of projects we need to run through, and we're gearing up. Again, there's a lot of contention between which instruments we're going to ship to customers and which ones we're deploying internally. The most contentious sort of that whole issue of which instruments go where is the most contentious, single most contentious issue in the company right now. And very early, but the scope of projects and demand is really diverse. Certainly, lots of academic projects, but a lot of biopharma, translational. We mentioned, just because it's kind of fun, Procter & Gamble is an example of a customer, just someone that would not have expected as your typical life science tools sort of target. But yeah, like a really, really nice diversity.

I think it's a great leading indicator, yet another leading indicator for demand that's going to be coming. Obviously, we've talked about, we've got lots of orders, and we're going to be, for the foreseeable future, we're going to be constrained by our ability to produce and deploy the instruments. The longer term science, what we're seeing from CRS, are also really positive.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

I guess, just thinking a little bit about the longer-term path. Talk a little bit about just how you think about the clinical pathway here too. Pharma's a nice bridge, obviously, and there's a lot of momentum here over the next couple years, but talk about timelines for clinical adoption, in your view, around spatial in particular.

Serge Saxonov
CEO, 10x

Yeah. We see a lot of potential both in single-cell and spatial. For single-cell and the kind of model of blood-based monitoring. For spatial, a lot of different applications, especially in oncology. I think there's a huge unmet need right now. There's these new generations of therapies that are like massive numbers that are already there, that are coming, more of them coming, that are really focused on targeting expression markers. So ADCs, there's lots of other type T-cell, bispecifics, T-cell engagers, all these different drugs and all these new modalities that are meant to target cells and expression markers, right? For these, we don't really have great diagnostics. We have one-off, like IHC, that's what people run. But that's good if you have one particular question in mind, one particular drug, and you decide yes or no between the drug.

If you have several choices, now that's no longer enough. You need an assay that can comprehensively profile multiple targets at once, and that's by definition is a spatial, maybe single-cell assay, right? So, we know there's a huge potential. When we talk to people out there in the community, whether it's scientists or researchers, or whether it's researchers or physicians, clearly there's a big need. We see it as unambiguously the future, and we feel like we also are in a good position to accelerate their future. We're engaging with multiple medical centers around the world, building up and running clinical cohorts to generate clinical evidence to show kind of correlations of these spatial biomarkers with clinical outcomes. There's a lot of conviction that that's kind of the future, but no one has really run the right kinds of experiments to generate that.

We are doing that. We will talk more about in the future, but a whole number of collaborations and things are going really well on that front. We are also building out a CLIA lab to start proving out some of these concepts early on as well. Again, when I go out there, I talk to quite a few physicians and clinicians who tell me, "Well, if these tests, the spatial single cell were available, I would send my patient samples there." That is part, again, early days, but I think there is huge potential there. I think we are in a unique position to really accelerate the arrival of that future.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

I guess, is the strategy in opening a CLIA lab on running LDTs or supporting translational biomarker programs for your partners?

Serge Saxonov
CEO, 10x

At this stage, first step is actually an LDT to enable, because we have this demand that is coming at us. For one, it is just like that service kind of needs to exist out there. We will take it from there and probably scale up as we go forward.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

I think one of the things we hear is just clinical adoption for spatial is gated by lack of standardization analytics, workflow integration into pathology. How do you think about the need to develop on those fronts?

Serge Saxonov
CEO, 10x

Yeah. I think it is kind of interesting. I mean, that is one of the things that was exciting to us about spatial from the very beginning. It kind of marries these worlds of genomics and pathology that previously kind of existed apart and had a lot of discomfort in sort of like overlapping and communicating. We felt that firsthand with a lot of our previous generations of products. But especially with starting with Xenium now, with Atera, you are really bringing these, like technologically and workflow-wise, you are really bringing those worlds together. It is very much, with Atera now, you can use standard off-the-shelf slides.

You do H&E on them, and then you get this, in addition to that, this insanely detailed molecular profiling of every single cell, like single molecule readout of what is going on in a format that, again, is very familiar to the world of pathology as well, right? It is these imaging-based slides. It very naturally expands. There is this sort of familiarity of the workflow and the format that you see with pathologists. It extends from that, but extends into sort of these new worlds of therapeutics that are just exploding right now in their number. The other thing that is particularly exciting now, of course, with the AI, you also kind of now have the means to address the problem of inference, right?

Because, yeah, one thing to produce the data, the other thing is to condense all those insights into something straightforward that you can make a clinical decision based off of. All this new AI, the progress in AI gives you the means of extracting those insights and condensing them in a really straightforward way. The last bit I would also point to is that with Atera, the workflow is becoming more and more straightforward. With what we have talked about coming in the future on the platform in terms of automation, on instrument automation, we anticipate that actually that workflow will become probably the simplest, the most straightforward workflow you have in genomics, period. I mean, literally slide goes in, data comes out. All of those pieces together create a really great substrate for interface with pathology and ultimate clinical adoption.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

I guess, how do you think about the competitive landscape? Obviously, there has been a fair amount of consolidation, NanoString gone, Fluidigm gone. I mean, just how do you think about your moat here?

Serge Saxonov
CEO, 10x

Well, our moat is always like build the very best products and keep pushing in our R&D. I think our history has been a great demonstration of the power of that approach. We feel really good where we are. I think we are probably multiple generations ahead of others, whether you look at any kind of product line, you look at us here. But especially when you look at Atera, there's so much innovation that has gone into it, so many, like across many years. Of course, we're not stopping here.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

Maybe just last one, 30 seconds left on inorganic M&A. Just how do you see the opportunity set there, and how much of a priority is that?

Serge Saxonov
CEO, 10x

Well, look, we've been very focused making sure that our fundamentals of our business are really sound. We put a lot of focus on efficiency, especially last year, but since then as well, to kind of make sure the business is operating really well. Our P&L looks really good, and we've generated close to $100 million of cash in the last 12 months. So we're in a really good position. We've got the balance sheet to take advantage of potential opportunities if they come along. But for us, it's always like it's got to be like a really good strategic rationale for making moves. If there's something out there that makes sense given the strategy, we will take advantage of it as we've done in the past.

Tycho Peterson
Managing Director and Senior Equity Analyst, Jefferies

Great. We'll leave it at that. Thanks.

Serge Saxonov
CEO, 10x

Thank you.